Merck & Co., Inc.
MRK
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $378.3B
$151.01
▼ -1.37%
P/E
120.80
Mkt Cap
$378.3B
52-Wk Range
$77.58–$156.92
52-Week Range
$77.58 - $156.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 82.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified therapeutic portfolio spanning high-demand disease areas with strong patent protection and pipeline depth
- Dual revenue streams from human pharmaceuticals and animal health, reducing dependence on single market segment
- Strategic partnerships with leading biotech and pharmaceutical companies accelerating innovation in breakthrough therapies like long-acting HIV treatments
- Established global distribution network and trusted relationships with healthcare providers, hospitals, and government agencies
- 132+ years of operational history and brand recognition providing competitive credibility and regulatory expertise
Bear Case
2 risks
- Low volatility (beta 0.2).
- Extreme premium - high expectations embedded
Growth
Stable outlook
Aging global population increasing demand for oncology, cardiovascular, and immunology treatments
Value
Extreme premium - high expectations embedded
Momentum
Hot
+27.4% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Solid
2.19% yield
Smart-money signal
Who's buying MRK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 4, 2026
Reported EPS of -$0.13 vs -$0.27 consensus (+51.9% surprise). Revenue of $16.6B vs $16.4B expected (+1.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+51.9%
Revenue trend · last 8Q
—
+7%
-2%
-2%
+4%
+4%
+5%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$16.7B
$15.6B
$15.5B
$15.8B
$17.2B
$16.3B
$16.3B
$16.6B
Margins · last 8Q
Gross
—
Operating
—
Profit
-8.0%
Wall Street consensus
17 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
$155.00
▲ +2.6% vs $151.01
Latest: Wolfe Research · Aug 25, 2026
3 analysts covering
vs Industry
How MRK stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related